Barclays Maintains Overweight on Teladoc Health, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Steve Valiquette has maintained an Overweight rating on Teladoc Health (TDOC) but has lowered the price target from $25 to $20.

April 26, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays maintains an Overweight rating on Teladoc Health but lowers the price target from $25 to $20.
The reduction in the price target by Barclays, despite maintaining an Overweight rating, could lead to a negative short-term sentiment among investors. This adjustment reflects a revised valuation basis by the analyst, potentially due to factors affecting Teladoc's market position or financial outlook. Such a move often results in a short-term negative impact on the stock price as investors adjust their expectations based on the new target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100